Eton Pharmaceuticals, Inc.
ETONHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. With a market capitalization of $1.16B, it sits in small-cap territory. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Market Cap
$1.16B
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
22.51
EPS (TTM)
$-0.06
EPS (Fwd)
$1.88
ROE
-5.4%
ROA
4.8%
Cash
$19.7M
Total Debt
$31.3M
Free CF
$2.4M
52W Change
181.8%
Annual Financials
Cash vs Debt
The company holds $19.7M in cash, though total debt stands at $31.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $2.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -5.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $21.3M (2022) to $80.0M (2025), reflecting a 276% increase over the period.
Investors considering Eton Pharmaceuticals, Inc. should weigh the typical risks associated with ETON's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing ETON's risk profile alongside its fundamentals and technical indicators provides a more complete picture.